FDA Approves ZOLEDRONIC ACID — Eugia US LLC

# FDA Approves Generic Zoledronic Acid Intravenous Formulation Eugia US LLC has received FDA approval for its generic zoledronic acid intravenous formulation (ANDA209125), expanding the competitive landscape in the osteoporosis and cancer supportive care market and potentially reducing treatment costs for patients requiring bisphosphonate therapy. The approval enables Eugia to capture market share from branded Reclast and other zoledronic acid competitors, benefiting from a large patient population dependent on this established therapeutic option.